Skip to content
OpenCapital
Get started

Envoy Medical COCH Long-term portion of accrued product warranty

Other financials

Income statement

See full
Revenue$39.0K-15.2%
Gross profit-$274.0K-52.2%
Operating income-$6.0M-16.7%
Net income-$4.4M+12.9%
EPS (diluted)-$0.08+72.4%

Balance sheet

See full
Cash & equivalents$25.3M+376%
Total debt$919.0K-2.8%
Total equity$10.2M+142%
Total assets$29.8M+187%

Cash flow

See full
Operating cash flow-$6.1M-62.7%
CapEx$172.0K—
Free cash flow-$5.9M-28.5%

Valuation

See full
Market cap$61M+83.5%
P/S260.7×+111×

Profitability

See full
Gross margin-310.7%+31.6pp
Operating margin-9,881.2%+805pp
Net margin-9,875.6%+771pp
FCF margin-7,626.6%-652pp

Returns & leverage

See full
Return on equity328.7%—
Debt / equity0.1×—
Current ratio2.3×+1.2×

Where this comes from

Reported directly by Envoy Medical in its filing.

Tagged under the XBRL concept us-gaap:ProductWarrantyAccrualNoncurrent.

The official record: Envoy Medical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Envoy Medical's long-term portion of accrued product warranty.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Envoy Medical's long-term portion of accrued product warranty?
Envoy Medical (COCH) reported long-term portion of accrued product warranty of $1.55M in Q1 2026.
How has Envoy Medical's long-term portion of accrued product warranty changed year-over-year?
Envoy Medical's long-term portion of accrued product warranty decreased by 12.5% year-over-year, from $1.77M to $1.55M.
What is the long-term trend for Envoy Medical's long-term portion of accrued product warranty?
Over 2 years (2023 to 2025), Envoy Medical's long-term portion of accrued product warranty has grown at a -8.6% compound annual growth rate (CAGR), from $1.92M to $1.61M.